Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Howard I. Scher, Andrew J. Armstrong, Michael J. Morris et al.|Journal of Clinical Oncology|2016Cited by 1.6k
Intermittent versus Continuous Androgen Deprivation in Prostate CancerMaha Hussain, Ian M. Thompson, George Wilding et al.|New England Journal of Medicine|2013Cited by 568
Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated ARser81Farideh Mehraein‐Ghomi, George Wilding|Genes & Cancer|2015Cited by 15